FGB
Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]
As of the edition of 20 October 2026, FGB (fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain], UniProt P02675) has 6 drugs tested at it and 7 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P02675
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 42
- Disease areas
- Heart and blood vessels; Nervous system; Hormones; Nutrition and metabolism; Immune system; Bones, joints and muscles; Ear, nose and throat; Infections
- Registered trials of its drugs
- 28
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Alfimeprase | Stopped | Phase 3 | none listed |
| Gamma-aminobutyric acid | Marketed | Phase 2 | none listed |
| Plasminogen | Active | Phase 3 | none listed |
| Fibrinolysin, human | Marketed | Phase 2 | Ended 1976 |
| Ancrod | Went quiet | Phase 3 | none listed |
| Fibrinogen i 125 | Marketed | No phase stated | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 7 |
| Total on the list | 7 |